An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Oragenics to Participate in the 2022 BioFlorida Annual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Oragenics, Inc. (NYSE American: OGEN) is participating in the 2022 BioFlorida Annual Conference from November 2-4 in Miami. The company's President and CEO, Kim Murphy, will speak on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on November 3 at 2:05 p.m. Eastern Time, held at the Hyatt Regency Miami. Murphy will also engage in one-on-one meetings with investors. Oragenics is focused on developing therapies for infectious diseases, including an intranasal COVID-19 vaccine candidate.
Positive
None.
Negative
None.
TAMPA, Fla.--(BUSINESS WIRE)--
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.
Kim Murphy, President and CEO, will be participating on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on Thursday, November 3 from 2:05 p.m. to 3:05 p.m.
Panel:
BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases
Date:
Thursday, November 3, 2022
Time:
2:05 p.m. Eastern Time
Location:
Hyatt Regency Miami
Ms. Murphy will also be participating in BioFlorida’s one-on-one investor and business development meetings. Please contact LHA Investor Relations to schedule a meeting.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.
Oragenics, Inc. Michael Sullivan, Chief Financial Officer
813-286-7900
msullivan@oragenics.com
LHA Investor Relations
Tirth T. Patel 212-201-6614
tpatel@lhai.com
Source: Oragenics, Inc.
FAQ
What is Oragenics, Inc. participating in?
Oragenics, Inc. is participating in the 2022 BioFlorida Annual Conference, taking place from November 2-4 in Miami.
Who is representing Oragenics at the BioFlorida conference?
Kim Murphy, the President and CEO of Oragenics, will represent the company at the conference.
When and where is the panel discussion featuring Oragenics happening?
The panel discussion titled 'BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases' is scheduled for November 3, 2022, at 2:05 p.m. Eastern Time at the Hyatt Regency Miami.
What is the focus of Oragenics, Inc.?
Oragenics is dedicated to developing treatments for infectious diseases, including COVID-19, with an intranasal vaccine candidate and a program targeting antibiotic-resistant bacteria.
How can investors contact Oragenics for meetings during the conference?
Investors can contact LHA Investor Relations at tpatel@lhai.com to schedule one-on-one meetings with Oragenics.
